CD19 and diffuse large B-cell lymphoma: This study validates the clinical utility of CD19-specific cellular immunotherapies for high-risk B-cell malignancies, demonstrating therapeutic responses that fill critical gaps in relapsed/refractory ALL and DLBCL treatment paradigms.